CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 490 enrolled
Drug / intervention
No Interventionother
Likely dose
Not stated in record
Key inclusion· 6
  • Cough lasting ≥2 weeks
  • At least one additional TB clinical symptom (fever, weight loss, appetite loss, hemoptysis, dyspnea, chest pain, night sweats, or fatigue)
  • Chest X-ray findings suggestive of TB per pulmonologist or internist with pulmonology consultation
  • Age ≥18 years
Key exclusion· 4
  • Pregnancy
  • Serious liver disease
  • Chronic kidney disease
  • Psychiatric illness that might interfere with study compliance

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02758236
NCT02758236N/ACompleted

Tuberculosis Research of INA-RESPOND On Drug Resistance

Ina-Respond·observational·Posted May 2, 2016·Updated May 16, 2024

In Brief

An observational study evaluating No Intervention for Lung Tuberculosis and MDR TB. Completed, enrolled 490 participants across 7 sites.

Detailed Summary

This study is a prospective observational cohort study of TB patients who are treated or evaluated at 10 study sites. Patients presenting with cough for 2 weeks or longer with at least one additional TB symptom and a chest X-ray suggestive of TB, will be invited to be enrolled in the study. The signed informed consent will designate their willingness to participate on this study.

Study Details

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2, 2016
Enrollment StartFeb 13, 2017
Primary CompletionNov 30, 2018
Study CompletionApr 26, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.2 years ago

Interventions

No Interventionother

No Intervention